A new study has determined that Truvada is as safe to users as aspirin. Commonly known as PrEP — or pre-exposure prophylaxis — Truvada has been subject to numerous studies in recent years to determine its efficacy and safety in helping prevent HIV infection in users.
This latest study, published by the Infectious Diseases Society of America and Oxford University Press, comes from Noah Kojima and Jeffrey D. Klausner of UCLA’s School of Medicine. Five major studies on PrEP were compared with two major studies on the safety of aspirin — which an estimated 50 million Americans take. The researchers compared the prevalence of side-effects in the studies.
The studies examined reported “no serious irreversible effects… hospitalizations or deaths” among both men and women while taking PrEP. Reversible effects included mild decreases in creatinine levels and small decreases in bone density — though no serious complications were reported as a result of either of these factors. Other side effects included unintentional weight loss and a decrease in white blood cells. Aspirin, meanwhile, can cause major gastrointestinal bleeding and easy bruising, among other known side effects.
These are challenging times for news organizations. And yet it’s crucial we stay active and provide vital resources and information to both our local readers and the world. So won’t you please take a moment and consider supporting Metro Weekly with a membership? For as little as $5 a month, you can help ensure Metro Weekly magazine and MetroWeekly.com remain free, viable resources as we provide the best, most diverse, culturally-resonant LGBTQ coverage in both the D.C. region and around the world. Memberships come with exclusive perks and discounts, your own personal digital delivery of each week’s magazine (and an archive), access to our Member's Lounge when it launches this fall, and exclusive members-only items like Metro Weekly Membership Mugs and Tote Bags! Check out all our membership levels here and please join us today!